ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical

FOXO4-DRI

FOXO4-DRI

Also known as: FOXO4-DRI Senolytic, Proxofim

Overview

Key Facts

Primary Goal: Research and therapeutic applications of FOXO4-DRI

Disrupts the FOXO4-p53 interaction that keeps senescent cells alive. Liberates p53 to trigger mitochondrial apoptosis in senescent cells.

Dosing Information

Half-Life

~12-24 hours (estimated due to D-amino acid stability)

Typical Dose

5–20 mg

Frequency

Twice weekly for defined cycles

Cycle Length

2-4 weeks on, extended rest periods (months)

Administration Routes:
subcutaneousintravenous

Benefits

  • Selective elimination of senescent (zombie) cells
  • Reversal of age-related tissue dysfunction in animal models
  • Restored fur density and kidney function in aged mice
  • Potential to reduce chronic inflammation from senescent cell burden

Side Effects

Injection site reactionsmild
Potential for transient immune activation as senescent cells are clearedmild
Very limited human safety datamild
High cost and limited availabilitymild

Mechanism of Action

1

Disrupts the FOXO4-p53 interaction that keeps senescent cells alive

2

Liberates p53 to trigger mitochondrial apoptosis in senescent cells

3

Selectively targets cells with high FOXO4 nuclear localisation (senescent phenotype)

Contraindications

Do not use this peptide if any of the following apply:

  • Active cancer or pre-cancerous conditions
  • Immunocompromised individuals
  • Pregnancy or breastfeeding
  • No human safety profile established

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Preclinical

Published in Cell (2017) by de Keizer et al., FOXO4-DRI demonstrated selective clearance of senescent cells in naturally aged mice, resulting in restored fitness, fur density, and renal function. The D-retro-inverso design confers protease resistance and improved bioavailability. While one of the most scientifically compelling senolytic approaches, it remains strictly in preclinical research with no human trials completed. Its large size and synthesis complexity make it one of the most expensive research peptides.

Frequently Asked Questions

Common questions about FOXO4-DRI

UK-Specific Information

Exclusive data points and guidance for UK residents using FOXO4-DRI

UK Lab Testing

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With

Share on TikTok

Generate a trackable link to share this peptide information on TikTok